IL150987A0 - Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization - Google Patents
Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularizationInfo
- Publication number
- IL150987A0 IL150987A0 IL15098700A IL15098700A IL150987A0 IL 150987 A0 IL150987 A0 IL 150987A0 IL 15098700 A IL15098700 A IL 15098700A IL 15098700 A IL15098700 A IL 15098700A IL 150987 A0 IL150987 A0 IL 150987A0
- Authority
- IL
- Israel
- Prior art keywords
- polypeptides
- present
- cardiovascularization
- angiogenesis
- modulation
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 108010043026 HGF activator Proteins 0.000 title 1
- 102100031465 Hepatocyte growth factor activator Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/003565 WO2001053486A1 (en) | 1999-03-08 | 2000-02-11 | Compositions and methods for the treatment of tumor |
| PCT/US2000/006884 WO2001005972A1 (en) | 1999-07-20 | 2000-03-15 | Compositions and methods for the treatment of immune related diseases |
| US25366500P | 2000-11-28 | 2000-11-28 | |
| PCT/US2000/034756 WO2001059100A2 (en) | 2000-02-11 | 2000-12-19 | Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL150987A0 true IL150987A0 (en) | 2003-02-12 |
Family
ID=39048807
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15098700A IL150987A0 (en) | 2000-02-11 | 2000-12-19 | Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization |
| IL150987A IL150987A (en) | 2000-02-11 | 2002-07-30 | Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL150987A IL150987A (en) | 2000-02-11 | 2002-07-30 | Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6800604B2 (de) |
| EP (1) | EP1255829B1 (de) |
| JP (2) | JP2003527844A (de) |
| AT (1) | ATE440139T1 (de) |
| AU (1) | AU3075701A (de) |
| CA (1) | CA2398775A1 (de) |
| CY (1) | CY1109518T1 (de) |
| DE (1) | DE60042793D1 (de) |
| DK (1) | DK1255829T3 (de) |
| ES (1) | ES2330918T3 (de) |
| IL (2) | IL150987A0 (de) |
| PT (1) | PT1255829E (de) |
| WO (1) | WO2001059100A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030119113A1 (en) * | 1999-07-20 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2004032847A2 (en) * | 2002-10-07 | 2004-04-22 | Genentech, Inc. | Hepatocyte growth factor variants |
| WO2004104215A2 (en) * | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7) |
| BRPI0412885A (pt) * | 2003-07-18 | 2006-10-03 | Amgen Inc | polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimento hepatócito (hgf) |
| JP2007536931A (ja) * | 2004-05-12 | 2007-12-20 | ジェネンテック・インコーポレーテッド | 新規の遺伝子破壊、組成物およびそれらに関連する方法 |
| EP2301536B1 (de) | 2004-10-13 | 2014-04-09 | PTC Therapeutics, Inc. | Verbindungen zur Nonsense-Unterdrückung und Verfahren zu deren Verwendung |
| BRPI0817233A2 (pt) | 2007-09-28 | 2012-11-06 | Intrexon Corp | construções terapêuticas de gene de trca e bireatores para a expressão de moléculas bioterapêuticas, e usos das mesmas |
| US20110206704A1 (en) * | 2009-10-19 | 2011-08-25 | Genentech, Inc. | Methods and compositions for modulating hepatocyte growth factor activator |
| TW201119677A (en) * | 2009-10-19 | 2011-06-16 | Genentech Inc | Modulators of hepatocyte growth factor activator |
| US20130149788A1 (en) * | 2011-12-09 | 2013-06-13 | Cornell University | Assay for quantifying elemental sulfur levels in a sample |
| US10743996B2 (en) * | 2017-03-24 | 2020-08-18 | Robert L. Bundy | Amnion putty for cartilage repair |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| US5382569A (en) | 1991-05-16 | 1995-01-17 | Warner-Lambert Company | Endotherlin antagonists |
| ATE522621T1 (de) | 1993-04-05 | 2011-09-15 | Univ Utah Res Found | Diagnose und behandlung von williams syndrom |
| US5773223A (en) | 1993-09-02 | 1998-06-30 | Chiron Corporation | Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof |
| US5935924A (en) | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
| US5661122A (en) | 1994-04-15 | 1997-08-26 | Genentech, Inc. | Treatment of congestive heart failure |
| US5610134A (en) | 1994-04-15 | 1997-03-11 | Genentech, Inc. | Treatment of congestive heart failure |
| EP0755446B1 (de) | 1994-04-25 | 2006-09-13 | Genentech, Inc. | Cardiotrophin und verwendung davon |
| US5573762A (en) | 1995-04-24 | 1996-11-12 | Genentech, Inc. | Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy |
| EP0759467B1 (de) | 1995-07-24 | 2004-02-11 | Mitsubishi Chemical Corporation | Inhibitor des Hepatozytwachstumsfaktoraktivators |
| WO1997012629A1 (en) | 1995-10-05 | 1997-04-10 | Genentech, Inc. | Improved angiogenesis using hepatocyte growth factor |
| JPH1135480A (ja) * | 1997-07-15 | 1999-02-09 | Mitsubishi Chem Corp | プロテアーゼの活性亢進に起因する疾患の予防及び／または治療剤 |
| DE60035693T2 (de) * | 1999-07-20 | 2008-05-15 | Genentech, Inc., South San Francisco | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten |
-
2000
- 2000-12-19 AU AU30757/01A patent/AU3075701A/en not_active Abandoned
- 2000-12-19 IL IL15098700A patent/IL150987A0/xx unknown
- 2000-12-19 EP EP00990950A patent/EP1255829B1/de not_active Expired - Lifetime
- 2000-12-19 US US09/742,201 patent/US6800604B2/en not_active Expired - Lifetime
- 2000-12-19 AT AT00990950T patent/ATE440139T1/de active
- 2000-12-19 CA CA002398775A patent/CA2398775A1/en not_active Abandoned
- 2000-12-19 DE DE60042793T patent/DE60042793D1/de not_active Expired - Lifetime
- 2000-12-19 PT PT00990950T patent/PT1255829E/pt unknown
- 2000-12-19 WO PCT/US2000/034756 patent/WO2001059100A2/en not_active Ceased
- 2000-12-19 ES ES00990950T patent/ES2330918T3/es not_active Expired - Lifetime
- 2000-12-19 DK DK00990950T patent/DK1255829T3/da active
- 2000-12-19 JP JP2001558238A patent/JP2003527844A/ja active Pending
-
2002
- 2002-07-30 IL IL150987A patent/IL150987A/en not_active IP Right Cessation
-
2003
- 2003-12-11 US US10/733,890 patent/US20040132660A1/en not_active Abandoned
-
2009
- 2009-10-26 CY CY20091101110T patent/CY1109518T1/el unknown
-
2012
- 2012-07-19 JP JP2012160868A patent/JP2012246296A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE440139T1 (de) | 2009-09-15 |
| JP2003527844A (ja) | 2003-09-24 |
| WO2001059100A3 (en) | 2001-12-20 |
| PT1255829E (pt) | 2009-11-26 |
| JP2012246296A (ja) | 2012-12-13 |
| DE60042793D1 (de) | 2009-10-01 |
| EP1255829B1 (de) | 2009-08-19 |
| DK1255829T3 (da) | 2009-12-14 |
| IL150987A (en) | 2009-09-01 |
| US20040132660A1 (en) | 2004-07-08 |
| CA2398775A1 (en) | 2001-08-16 |
| EP1255829A2 (de) | 2002-11-13 |
| CY1109518T1 (el) | 2014-08-13 |
| WO2001059100A2 (en) | 2001-08-16 |
| US6800604B2 (en) | 2004-10-05 |
| AU3075701A (en) | 2001-08-20 |
| ES2330918T3 (es) | 2009-12-17 |
| US20020123091A1 (en) | 2002-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL202176A0 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
| WO2002008284A3 (en) | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis | |
| WO2002000690A3 (en) | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis | |
| CY1109518T1 (el) | Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης | |
| WO2000053753A3 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
| WO2000053757A3 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
| ATE357518T1 (de) | Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums | |
| ATE443074T1 (de) | Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren | |
| ATE541931T1 (de) | Il-17-homologe polypeptide und ihre therapeutische verwendung | |
| DK1032668T3 (da) | Fibroblast vækstfaktor 19 | |
| AU2003264419A1 (en) | Kdr peptides and vaccines containing the same | |
| WO2000053752A3 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
| EP1669371A3 (de) | Zusammensetzung und Verfahren zur Diagnose eines Tumors | |
| ATE432987T1 (de) | Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums | |
| ATE380195T1 (de) | Zusammensetzungen und verfahren zur behandlung von tumoren | |
| WO2002000711A3 (en) | Ev-vegf nucleic acids and polypeptides and methods of use | |
| WO2002018620A3 (en) | Neutrokine-alpha and neutrokine-alpha splice variant | |
| WO2003033658A3 (en) | Neutrokine-alpha and neutrokine-alpha splice variant | |
| WO2000066156A8 (en) | Death domain containing receptor 5 | |
| WO2001025433A3 (en) | Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization | |
| PT1212417E (pt) | Promoção ou inibição de angiogénese e cardiovascularização | |
| WO2001040464A8 (en) | Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization | |
| WO2002016611A3 (en) | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders | |
| EP1734051A3 (de) | Zusammensetzung und Verfahren zur Diagnose eines Tumors | |
| ATE295874T1 (de) | Differenzierungsfaktor der hypophyse und methoden zu seiner verwendung. |